The most recent Neurocrine Biosciences (NBIX) insider transaction: Eiry Roberts (Chief Medical Officer) received 8,314 shares as a grant or award on Nov 4, 2026, reported on Form 4 on Nov 5, 2026. So far in the quarter ending Dec 31, 2026, insiders were net buyers of 282 shares.
In the last 12 months, insiders at Neurocrine Biosciences made open-market sales of $77.43 million (498.65K shares) and bought no shares on the open market.
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Kevin Charles Gorman | Chief Executive Officer | 517,797 | 0 | 517,797 | 41.7% | 15 Sep, 2026 |
| 2 | Kyle Gano | Chief Executive Officer | 155,010 | 0 | 155,010 | 12.5% | 03 Nov, 2026 |
| 3 | Gary A Lyons | President And Ceo | 122,141 | 0 | 122,141 | 9.8% | 21 May, 2026 |
| 4 | Eric Benevich | Chief Commercial Officer | 67,297 | 0 | 67,297 | 5.4% | 15 Sep, 2026 |
| 5 | Darin Lippoldt | Chief Legal Officer | 56,793 | 0 | 56,793 | 4.6% | 15 Sep, 2026 |
| 6 | William H Rastetter | Director | 43,678 | 0 | 43,678 | 3.5% | 21 May, 2026 |
| 7 | Matt Abernethy | Chief Financial Officer | 42,808 | 0 | 42,808 | 3.4% | 15 Sep, 2026 |
| 8 | Malcolm Lloyd-Smith | Chief Integration Officer | 42,337 | 0 | 42,337 | 3.4% | 08 Feb, 2023 |
| 9 | Richard F Pops | Director | 37,798 | 0 | 37,798 | 3.0% | 21 May, 2026 |
| 10 | Eiry Roberts | Chief Medical Officer | 35,640 | 0 | 35,640 | 2.9% | 14 Feb, 2025 |
| 11 | Julie Cooke | Chief Human Resources Officer | 24,025 | 0 | 24,025 | 1.9% | 15 Sep, 2026 |
| 12 | Jude Onyia | Chief Scientific Officer | 22,647 | 0 | 22,647 | 1.8% | 15 Sep, 2026 |
| 13 | Ingrid Delaet | Chief Regulatory Officer | 18,289 | 0 | 18,289 | 1.5% | 15 Sep, 2026 |
| 14 | Stephen A Sherwin | Director | 14,860 | 0 | 14,860 | 1.2% | 03 Sep, 2026 |
| 15 | George J Morrow | Director | 10,386 | 0 | 10,386 | 0.8% | 03 Nov, 2026 |
| 16 | David W. Boyer | Chief Corp. Affairs Officer | 8,722 | 0 | 8,722 | 0.7% | 15 Sep, 2026 |
| 17 | Johanna Mercier | Director | 6,853 | 0 | 6,853 | 0.6% | 21 May, 2026 |
| 18 | Christine A Poon | Director | 4,753 | 0 | 4,753 | 0.4% | 21 May, 2026 |
| 19 | Shalini Sharp | Director | 4,088 | 0 | 4,088 | 0.3% | 21 May, 2026 |
| 20 | Sanjay Chandru Keswani | Chief Medical Officer | 3,281 | 0 | 3,281 | 0.3% | 15 Sep, 2026 |
| 21 | Leslie V Norwalk | Director | 2,430 | 0 | 2,430 | 0.2% | 30 Jul, 2026 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 04 Nov, 2026 | Eiry Roberts | Chief Medical Officer | Acquired A | 8,314 | $0.00 | $0 | 8,314 | Direct |
| 04 Nov, 2026 | Eiry Roberts | Chief Medical Officer | Acquired A | 1,506 | $0.00 | $0 | 1,506 | Direct |
| 01 Nov, 2026 | Kyle Gano | Chief Executive Officer | Acquired M | 614 | $0.00 | $0 | 155,342 | Direct |
| 30 Oct, 2026 | George J Morrow | Director | Acquired M | 300 | $53.64 | $16.09K | 10,686 | Direct |
| 01 Nov, 2026 | Kyle Gano | Chief Executive Officer | Disposed F | 332 | $146.10 | $48.51K | 155,010 | Direct |
| 30 Oct, 2026 | George J Morrow | Director | Disposed S | 300 | $149.00 | $44.70K | 10,386 | Direct |
| 01 Nov, 2026 | Kyle Gano | Chief Executive Officer | Disposed M | 614 | $0.00 | $0 | 1,228 | Direct |
| 02 Nov, 2026 | George J Morrow | Director | Acquired M | 7,500 | $53.64 | $402.30K | 17,886 | Direct |
| 02 Nov, 2026 | George J Morrow | Director | Disposed S | 1,900 | $144.98 | $275.45K | 15,986 | Direct |
| 02 Nov, 2026 | George J Morrow | Director | Disposed S | 4,300 | $145.86 | $627.19K | 11,686 | Direct |
| 02 Nov, 2026 | George J Morrow | Director | Disposed S | 1,300 | $146.76 | $190.78K | 10,386 | Direct |
| 03 Nov, 2026 | George J Morrow | Director | Acquired M | 7,200 | $53.64 | $386.21K | 17,586 | Direct |
| 03 Nov, 2026 | George J Morrow | Director | Disposed S | 100 | $158.18 | $15.82K | 17,486 | Direct |
| 03 Nov, 2026 | George J Morrow | Director | Disposed S | 100 | $162.05 | $16.21K | 17,386 | Direct |
| 03 Nov, 2026 | George J Morrow | Director | Disposed S | 600 | $163.71 | $98.22K | 16,786 | Direct |
| 03 Nov, 2026 | George J Morrow | Director | Disposed S | 1,226 | $164.74 | $201.97K | 15,560 | Direct |
| 03 Nov, 2026 | George J Morrow | Director | Disposed S | 908 | $165.71 | $150.46K | 14,652 | Direct |
| 03 Nov, 2026 | George J Morrow | Director | Disposed S | 1,466 | $166.77 | $244.49K | 13,186 | Direct |
| 03 Nov, 2026 | George J Morrow | Director | Disposed S | 1,500 | $167.72 | $251.59K | 11,686 | Direct |
| 03 Nov, 2026 | George J Morrow | Director | Disposed S | 1,300 | $168.53 | $219.09K | 10,386 | Direct |